Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: A systematic review

British Journal of Ophthalmology

Volumn 96, Issue 2, 2012, Pages 167-178

  Zechmeister Koss, Ingrid ^a   Huić, Mirjana ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Agency for Quality and Accreditation in Health   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

BLADDER CANCER; BLOOD PRESSURE; CATARACT; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; FOOT DISEASE; FOOT GANGRENE; FOOT ULCER; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFECTION; INTERMETHOD COMPARISON; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW DRUG DOSE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; REVIEW; SHAM PROCEDURE; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THORAX DISEASE; THROMBOEMBOLISM; VASCULAR DISEASE; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84856055811     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300674     Document Type: Review

References (23)

1. Royle P, Cummins E, Henderson R, et al. Ranibizumab for the Treatment of Diabetic Macular Oedema: a single technology appraisal. Aberdeen HTA Group. Aberdeen: University of Aberdeen, 2011.
2. Klein R, Klein B, Moss S, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-15. (Pubitemid 28509717)
3. Fraser C, D'Amico D. Prevention and treatment of diabetic retinopathy. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2011.
4. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009;(4):CD007419.
5. Micromedex Drugdex® Database. Thompson Reuters, 2011. http://www.thonsonhc.com
6. Goyal S, LaValley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15-27.
7. Karim R, Tang B. Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol 2010;4:493-517.
8. Nicholson B, Schachat A. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-30.
9. Gartlehner G. Internes Manual. Abläufe und Methoden. Part 2. 2nd edition. HTAProjektbericht no. 6. 2008:1-79.
10. Sharma S, Oliver-Fernandez A. Age-related macular degeneration and quality of life: how to interpret a research paper in health-related quality of life. Curr Opin Ophtalmol 2004;15:227-31. (Pubitemid 38638868)
11. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004;4:38.
12. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9. (Pubitemid 351447960)
13. Lam D, Lai T, Lee V, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009;29:292-9.
14. Michaelides M, Kaines A, Hamilton R, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86.e2.
15. Paccola L, Costa R, Folgosa M, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
16. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50.
17. Solaiman K, Diab M, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30:1638-45.
18. Diabetic Retinopathy Clinical Research Network, Elman M, Aiello L, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.e35.
19. Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405.
20. Nguyen Q, Shah S, Heier J, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.e1.
21. Cunningham E Jr, Adamis A, Altaweel M, et al Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57.
22. Fintak D, Shah G, Blinder K, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-9.
23. Wu L, Martinez-Castellanos M, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch for Clin & Exp Ophthalmol 2008;246:81-7. (Pubitemid 350167096)